


## Participant Flow:



**Baseline Characteristics:**

Table 1. Distribution of sociodemographic characteristics in T2DM patients.

	EG (n=35)		CG (n=33)		p
	N	%	N	%	
Gender					
Male	18	(51.4)	22	(66.7)	0.202
Female	17	(48.6)	11	(33.3)	
Age, mean $\pm$ SD	54.7 $\pm$ 6.1		54.8 $\pm$ 6.9		0.932
Duration of diabetes (year) <sup>a</sup>					
<5	16	48.5	12	36.4	0.273
5-10	10	30.3	8	24.2	
>10	7	21.2	13	39.4	
Education level					
Less than junior high school	7	20.0	6	18.2	0.976
High school	17	48.6	16	48.5	
Higher than technical school/college	11	31.4	11	33.3	
Baseline HbA1c(%), mean $\pm$ SD	7.0 $\pm$ 1.2		6.9 $\pm$ 1.2		0.881
Perceived oral health status					
Very good / Good	8	22.9	4	12.1	0.172
Common	20	57.1	16	48.5	
Very poor/ Poor	7	20.0	13	39.4	

Abbreviation: Experimental group (EG), Control group(CG)

<sup>a</sup> Missing values represent refusal to answer or forgetting the answer.

# Outcome Measures:

(Not Yet Published)

Table 1. The effect of the periodontal care intervention on periodontal parameters among T2DM patients.

	EG (n=35)	CG (n=33)		
	diff, mean±SD	diff, mean±SD	β(SE)	95%CI
PPD				
Group (EG) x Time (1 month follow-up)	-0.5±0.4 <sup>a</sup>	-0.2±0.3	-0.24(0.08)	(-0.40,-0.08)*
Group (EG) x Time (3 month follow-up)	-0.5±0.5 <sup>b</sup>	-0.4±0.4	-0.13(0.11)	(-0.34,0.08)
Group (EG) x Time (6 month follow-up)	-0.4±0.5 <sup>c</sup>	-0.3±0.5	-0.11(0.12)	(-0.34,0.13)
CAL				
Group (EG) x Time (1 month follow-up)	-0.4±0.4	-0.1±0.3	-0.24(0.08)	(-0.40,-0.07)*
Group (EG) x Time (3 month follow-up)	-0.3±0.4	-0.2±0.4	-0.09(0.11)	(-0.31,0.13)
Group (EG) x Time (6 month follow-up)	-0.3±0.5	-0.2±0.5	-0.09(0.13)	(-0.35,0.17)
GI				
Group (EG) x Time (1 month follow-up)	-0.8±0.5	-0.8±0.8	0.02(0.14)	(-0.26,0.30)
Group (EG) x Time (3 month follow-up)	-0.9±0.7	-1.1±0.6	0.17(0.16)	(-0.15,0.49)
Group (EG) x Time (6 month follow-up)	-0.8±0.8	-1.0±0.8	0.17(0.17)	(-0.17,0.51)
PI				
Group (EG) x Time (1 month follow-up)	-0.6±0.6	-0.8±0.8	0.19(0.15)	(-0.10,0.47)
Group (EG) x Time (3 month follow-up)	-0.7±0.7	-1.0±0.9	0.31(0.17)	(-0.03,0.64)
Group (EG) x Time (6 month follow-up)	-0.7±0.8	-1.0±0.8	0.23(0.18)	(-0.12,0.58)
BOP (%)				
Group (EG) x Time (1 month follow-up)	-26.5±19.5	-20.5±26.0	-6.61(4.87)	(-16.15,2.93)
Group (EG) x Time (3 month follow-up)	-29.5±23.0	-28.7±26.4	-3.00(5.62)	(-14.02,8.03)
Group (EG) x Time (6 month follow-up)	-30.4±26.9	-26.1±29.8	-1.93(5.94)	(-13.58,9.71)

Abbreviation: Experimental group (EG), Control group(CG), probing pocket depth (PPD), clinical attachment level (CAL), gingival index (GI), plaque index (PI), bleeding on probing (BOP), Confidence Interval (CI)

<sup>a</sup>the difference between baseline and 1 month follow-up within the group

<sup>b</sup>the difference between baseline and 3 month follow-up within the group

<sup>c</sup>the difference between baseline and 6 month follow-up within the group

β(SE), 95%CI: adjust age, gender, education level and duration of diabetes by linear regression in Generalized Estimating Equations (GEE); Reference: Control group x Time (baseline); \*P<0.05

Table 2. The effect of the periodontal care intervention on periodontal parameters among T2DM patients.

	EG (n=35)	CG (n=33)		
	diff, mean±SD	diff, mean±SD	β(SE)	95%CI
Oral health related quality of life				
Group (EG) x Time (1 month follow-up)	-0.9±4.5 <sup>a</sup>	-4.0±6.5	3.09(1.16)	(0.82,5.37)*
Group (EG) x Time (3 month follow-up)	-2.9±4.8 <sup>b</sup>	-4.1±6.1	1.20(1.48)	(-1.73,4.07)
Group (EG) x Time (6 month follow-up)	-3.2±5.2 <sup>c</sup>	-4.3±6.5	0.94(1.66)	(-2.32,4.19)

Abbreviation: Experimental group (EG), Control group(CG)

<sup>a</sup>the difference between baseline and 1 month follow-up within the group

<sup>b</sup>the difference between baseline and 3 month follow-up within the group

<sup>c</sup>the difference between baseline and 6 month follow-up within the group

β(SE), 95%CI: adjust age, gender, education level and duration of diabetes by linear regression in Generalized Estimating Equations (GEE); Reference: Control group x Time (baseline); \**P*<0.05

**Adverse Events:**

There were no adverse events associated with this trial.